de Leeuw Frank-Erik, Korf Esther, Barkhof Frederik, Scheltens Philip
Department of Neurology, University Medical Center St. Radboud, Nijmegen, The Netherlands.
Stroke. 2006 Sep;37(9):2248-52. doi: 10.1161/01.STR.0000236555.87674.e1. Epub 2006 Aug 10.
Medial temporal lobe atrophy (MTA) is a hallmark of Alzheimer disease (AD). Its progression is often seen during the course of AD, but its frequency and risk factors remain unclear.
We investigated MTA in 35 patients with AD from whom sequential magnetic resonance imaging scans were available. White matter lesions (WML; for the periventricular [PV] and subcortical [SC] regions separately) and MTA were rated semiquantitatively.
In approximately two thirds of all patients, progression of MTA was found. The mean MTA progression was 0.8 (standard deviation: 0.5) and 0.3 (standard deviation: 0.4) for patients with or without PVWML at baseline (P=0.01). Patients who showed progression of PVWML over the course of their disease had a significantly higher mean progression of MTA than those without PVWML progression (0.9 [SD: 0.4]) and 0.4 [SD: 0.5]; P=0.01). Patients with PVWML at baseline had a 40-fold increased risk for progression of MTA compared with those without baseline PVWML (odds ratio=40.0, 95% CI=1.3 to 1.2x10(3), P=0.03). Patients with progression of PVWML during the course of the disease had an increased risk for MTA progression (odds ratio=3.7 per unit increase of progression of PVWML, 95% CI=1.1 to 12.9, P=0.04). There was higher risk for progression of MTA for those with progression of PVWML than those without (odds ratio=10.9, 95% CI=1.0 to 122.5, P=0.05). This was not found for SCWML.
Our findings suggest that the presence and the progression of WML are associated with progression of MTA in AD. WML may be a predictor of the course of the disease and a potential treatment target in AD.
内侧颞叶萎缩(MTA)是阿尔茨海默病(AD)的一个标志。其进展在AD病程中较为常见,但其发生频率及危险因素仍不明确。
我们对35例有连续磁共振成像扫描资料的AD患者的MTA情况进行了研究。对白质病变(WML;分别针对脑室周围[PV]和皮质下[SC]区域)和MTA进行半定量评分。
在所有患者中,约三分之二发现有MTA进展。基线时伴有或不伴有PVWML的患者,其MTA平均进展分别为0.8(标准差:0.5)和0.3(标准差:0.4)(P=0.01)。在疾病过程中PVWML有进展的患者,其MTA平均进展显著高于PVWML无进展的患者(分别为0.9[标准差:0.4]和0.4[标准差:0.5];P=0.01)。基线时有PVWML的患者,其MTA进展风险比无基线PVWML的患者高40倍(比值比=40.0,95%可信区间=1.3至1.2×10³,P=0.03)。疾病过程中PVWML有进展的患者,其MTA进展风险增加(PVWML进展每增加一个单位,比值比=3.7,95%可信区间=1.1至12.9,P=0.04)。PVWML有进展的患者比无进展的患者发生MTA进展的风险更高(比值比=10.9,95%可信区间=1.0至122.5,P=0.05)。SCWML未发现这种情况。
我们的研究结果表明,WML的存在和进展与AD患者MTA的进展相关。WML可能是疾病进程的一个预测指标,也是AD潜在的治疗靶点。